Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 in Multiple Myeloma post-ASCT
NCT01251172Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of RO4929097 in multiple myeloma (MM), sponsored by National Cancer Institute. Planned start Dec 2010; status: withdrawn.
02
Drugs
RO4929097
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01251172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251172.